Olverembatinib (HQP-1351)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 11:19, 16 August 2023 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Third-generation TKI ==Diseases for which it is used== *Chronic myeloid leukemia ==History of changes in NMPA indication== *2021-11: Initial cond...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Third-generation TKI

Diseases for which it is used

History of changes in NMPA indication

  • 2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant CML-CP or CML-AP harboring the T315I mutation as confirmed by a validated diagnostic test. (Based on HQP1351CC203)

Also known as

  • Code name: HQP-1351
Retrieved from "https://hemonc.org/w/index.php?title=Olverembatinib_(HQP-1351)&oldid=76665"